替万替尼对CYP酶及P-糖蛋白探针药物药代动力学影响的评价
本研究为1期开放标签交叉试验,在28例晚期实体瘤患者中使用鸡尾酒探针法评估替万替尼360 mg每日两次对CYP1A2、CYP2C9、CYP2C19、CYP3A4及P-糖蛋白底物药代动力学的影响。结果显示替万替尼对CYP探针药物影响极小或无影响,但降低P-糖蛋白底物地高辛的系统暴露。
要点
- 替万替尼360 mg每日两次对CYP1A2、CYP2C9、CYP2C19、CYP3A4底物药代动力学影响极小或无影响。
- 替万替尼降低P-糖蛋白底物地高辛的系统暴露,AUC比值为0.69(90%CI 0.51-0.94)。
- 临床合用P-糖蛋白底物时需关注暴露降低可能影响疗效。
核心结论
- 替万替尼360 mg每日两次对CYP1A2、CYP2C9、CYP2C19和CYP3A4底物探针药物的药代动力学影响极小或无影响。
- 替万替尼降低P-糖蛋白底物地高辛的系统暴露。
研究设计与样本
- 1期、开放标签、交叉研究,在28例晚期癌症患者中使用鸡尾酒探针法。
- 患者单次单独接受探针药物,并在替万替尼360 mg每日两次治疗5天后再次接受探针药物。
主要发现
- 替万替尼存在/不存在时AUClast几何最小二乘均值比值(90%CI):咖啡因0.97(0.89-1.05)、S-华法林0.88(0.76-1.02)、奥美拉唑0.89(0.60-1.31)、咪达唑仑0.83(0.67-1.02)、地高辛0.69(0.51-0.94)。
- Cmax比值类似,地高辛存在/不存在时Cmax比值为0.75(0.60-0.95)。
关键数值与推荐
- CYP1A2探针为咖啡因,CYP2C9探针为S-华法林,CYP2C19探针为奥美拉唑,CYP3A4探针为咪达唑仑,P-糖蛋白探针为地高辛。
- 替万替尼剂量为360 mg每日两次,治疗5天后进行探针药物评估。
临床怎么用
- 与CYP1A2、CYP2C9、CYP2C19、CYP3A4底物合用时预计无需常规剂量调整。
- 与P-糖蛋白底物(如地高辛)合用时需警惕底物暴露降低,应监测疗效或考虑调整剂量。
局限性
- 研究为1期开放标签交叉设计,样本量28例。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: This phase 1, open-label, crossover study sought to evaluate drug-drug interactions between tivantinib and cytochrome P450 (CYP) substrates and tivantinib and P-glycoprotein. METHODS: The effect of tivantinib doses on the pharmacokinetics of the probe drugs for CYP1A2 (caffeine), CYP2C9 (S-warfarin), CYP2C19 (omeprazole), and CYP3A4 (midazolam), and for P-glycoprotein (digoxin) was investigated in 28 patients with advanced cancer using a cocktail probe approach. Patients received single doses of probe drugs alone and, after 5 days of treatment, with tivantinib 360 mg twice daily. RESULTS: The ratios of geometric least squares mean (90% confidence interval) for the area under the concentration-time curve from time zero to the last quantifiable concentration in the presence/absence of tivantinib were 0.97 (0.89-1.05) for caffeine, 0.88 (0.76-1.02) for S-warfarin, 0.89 (0.60-1.31) for omeprazole, 0.83 (0.67-1.02) for midazolam, and 0.69 (0.51-0.94) for digoxin. Similar effects were observed for maximum plasma concentrations; the ratio for digoxin in the presence/absence of tivantinib was 0.75 (0.60-0.95). CONCLUSIONS: The data suggest that tivantinib 360 mg twice daily has either a minimal or no effect on the pharmacokinetics of probe drugs for CYP1A2, CYP2C9, CYP2C19 and CYP3A4 substrates, and decreases the systemic exposure of P-glycoprotein substrates when administered with tivantinib.
引用
- Tachibana M, Papadopoulos KP, Strickler JH, et al. Evaluation of the pharmacokinetic drug interaction potential of tivantinib (ARQ 197) using cocktail probes in patients with advanced solid tumours. Br J Clin Pharmacol. 2017. PMID: 28865153. doi:10.1111/bcp.13424
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。